Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05472779
Status:
RECRUITING
Last Update Posted:
2024-01-09
First Post:
2022-07-21
Brief Title:
Periurethral Vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections
Sponsor:
Stephanie Wang Zuo
Organization:
University of Pittsburgh
Study Overview
Official Title:
Periurethral Vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections TAPER Techniques of APplying Vaginal Estrogen for Prevention of Recurrent Urinary Tract Infections Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAPER
Brief Summary:
Due to rising antibiotic resistance there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections rUTI one of which is the safe and efficacious option of vaginal estrogen therapy Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week but some providers counsel patients with rUTI to apply a small pea-sized amount to the periurethral area This ideally reduces the amount of vaginal estrogen used while attaining a similar effect However to date there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None